Position: Home>About Us>Milestones
Milestones


Dec. 2016

Oct. 2016

Sep. 2016

Genor got the 5rd and 6rd CTA from CFDA for GB226 and GB224, two are novel antibodies.

Genor got the 4rd CTA (clinical trial approval) from CFDA (China FDA) for GB222, a bevacizumab biosimilar.

Genor got the 3rd CTA (clinical trial approval) from CFDA (China FDA) for GB241, an rituximab biosimilar.

Feb. 2016

Genor filed its 7rd IND in China.

Dec. 2015

Genor's subsidiary constructed "therapeutic monoclonal antibody drugindustrialization project" in yuxi, Yunnan province.

Oct. 2015

Genor filed its 6rd IND in China.

Sep. 2015

Genor was awarded its 3rd grant of "National Key Drugs R&D Program" by the China central government.

Aug. 2015

Genor successfully introduced new strategic investors, will inject 500 million RMB toGenor Biopharma in the first round.

May. 2015

Genor joint itspartner filed its 5rd IND in China.

Apr. 2015

Genor’s Adalimumabbiosimilar (GB232) started Phase I clinical trial in South Korea.

Mar. 2015

Genor signedstrategic cooperation agreement with Hangzhou Tigermed.

Jan. 2015

Genor got the 2nd CTA(clinical trial approval) from CFDA (China FDA) for GB242, an infliximabbiosimilar.

Oct. 2014

Genor filed its 4rd IND in China.

Aug. 2014

One of Genor's products received clinical trial approval in South Korea.

May. 2014

Genor was awarded its 2nd grant of "National Key Drugs R&D Program" by the China central government.

May. 2014

One of Genor's products received clinical trial approval in South Korea.

Dec. 2013

One of Genor's products filed IND in South Korea.

Dec. 2013

Genor was acquired by Walvax, a public listed biopharma.

Jul. 2013

Genor got the CTA (clinical trial approval) from CFDA (China FDA) for GB221, a trastuzumab biosimilar.

Jun. 2013

Genor was awarded its 1st grant of "National Key Drugs R&D Program" by the China central government.

May. 2013

Genor and RuiYi entered into a partnership to the development of GB224 (RYI-008), a novel therapeutic mAb for treating autoimmune diseases and cancer.

Mar. 2013

Genor filed its 3rd IND in China.

Jun. 2012

Genor filed its 2nd IND in China.

Dec. 2011

Genor inaugurated and moved into its current new site of more than 6000 square meters.

Nov. 2011

Genor initiated fist in human trial of its 1st therapeutic mAb drug in Australia.

May. 2011

Genor filed its 1st IND in China.

Feb. 2011

Genor signed a CMO service contract with a global top 5 pharmaceutical company, which indicates international recognition for its process, analytical and production capability.

Mar. 2010

Dr. Joe Zhou, the CEO of Genor, was elected as a member of the TOP 1000 TALENTS program in China.

Dec. 2007

Genor Biopharma came into being.